Novel therapeutic targets for cholestatic and fatty liver disease

Michael Trauner, Claudia Daniela Fuchs

ABSTRACT

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas. Nuclear receptors (NRs) are ligand-activated transcriptional regulators of key metabolic processes including hepatic lipid and glucose metabolism, energy expenditure and bile acid (BA) homeostasis, as well as inflammation and fibrosis and cellular proliferation. Dysregulation of these processes contributes to the pathogenesis and progression of cholestatic as well as fatty liver disease, placing NRs at the forefront of novel therapeutic approaches. This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed. Moreover, novel liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs. Apart from FXR ligands, BA signalling can be targeted by mimetics of FXR-activated fibroblast growth factor 19, modulation of their enterohepatic circulation through uptake inhibitors in hepatocytes and enterocytes, as well as novel BA derivatives undergoing cholehepatic shunting (instead of enterohepatic circulation). Other therapeutic approaches more directly target inflammation and/or fibrosis as critical events of disease progression. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of these complex and multifactorial disorders.

INTRODUCTION

Although cholestatic and non-alcoholic fatty liver disease (NAFLD) are aetiologically different, they share several key pathophysiological mechanisms which may be amenable to novel therapeutic interventions. Notably, therapeutic concepts for both disease areas have often been promoted by eminent scientists who were active on both sides with ursodeoxycholic acid (UDCA) being a common denominator for a considerable amount of time.1 2 Much has changed in recent years due to our significant advances in understanding the molecular mechanism of bile acid (BA) and lipid metabolism, their regulation and what goes awry in disease.3 4 NAFLD has become the most common chronic liver disease globally affecting up to 30% of the adult population and cirrhosis due to non-alcoholic steatohepatitis (NASH) as potentially reversible disease can be targeted by novel and effective therapeutic strategies still significantly lagging behind other areas of hepatology. While numbers of patients with primary biliary cholangitis (PBC) listed for liver transplantation, have decreased by almost 50% despite opposing epidemiological trends, possibly due to the therapeutic impact of UDCA, PBC has become the leading indication for liver transplantation among patients with immune-mediated liver diseases.5 6 Much has changed in recent years due to our significant advances in understanding the molecular mechanism of bile acid (BA) and lipid metabolism, their regulation and what goes awry in disease.7 Thus, both cholestatic and fatty liver diseases urgently require novel and effective therapies to prevent or at least reduce the growing burden of liver transplantation and death.

Key message

► Cholestatic and non-alcoholic fatty liver disease share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas.
► Pharmacological ligands for nuclear (hormone) receptors (NRs) regulate key metabolic pathways such as bile acid (BA), lipid, glucose and energy metabolism, as well as inflammation and fibrosis placing them at the forefront of current therapeutic developments.
► Therapeutic modulation of BA signalling through pharmacological ligands for the nuclear bile acid receptor (farnesoid-X receptor (FXR)), mimetics of the FXR-induced gut hormone ‘fibroblast growth factor 19’ and side-chain modified BA (nor-ursodeoxycholic acid) have shown promising clinical results.
► Novel pharmacological ligands for specific isoforms of peroxisome proliferator-activated receptors and liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs.
► Combination strategies synergistically targeting metabolic disturbances, intestinal dysbiosis, inflammation and fibrosis may be necessary for successful treatment of these complex and multifactorial disorders.

To cite: Trauner M, Fuchs CD. Gut 2021;0:1–16. doi:10.1136/gutjnl-2021-324305

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
BA toxicity as result of impaired hepatobiliary excretory function may become more critical when liver disease is already too advanced (see below). Direct antifibrotic therapeutic actions may be attractive targets for treatment of metabolic and cholestatic liver diseases.

**SHARED PATHOGENETIC PRINCIPLES AS TARGETS FOR THERAPEUTIC INTERVENTIONS**

NAFLD is considered the hepatic manifestation of metabolic syndrome, where lipid overload as a result of increased fatty acid influx due to insulin resistance in the adipose tissue leads to metabolically stressed hepatocytes with activation of cell death and proinflammatory signalling pathways. NASH may therefore be grossly viewed as an influx problem due to increased fatty acid load with consecutive lipotoxicity, while cholestasis may be considered an efflux problem resulting in accumulation of potentially cytotoxic and proinflammatory BAs and other cholephilic factors. In both scenarios failed or inadequate metabolic adaptation to substrate overload results in sublethal cell stress or even cell death with release of mediators and extracellular vesicles driving inflammation and fibrosis. Interestingly, BA toxicity as result of impaired hepatobiliary excretory function and functional (micro)cholestasis may also be involved in the pathogenesis of NASH. Given the central role of BAs in regulating hepatic lipid metabolism, dysregulation of BA homeostasis and signalling may further contribute to abnormal lipid metabolism and lipotoxicity in NAFLD. Liver fibrosis is the consequence of a sustained woundhealing process caused by unresolved chronic cell injury and is characterised by excessive accumulation of extracellular matrix components produced by activated hepatic stellate cells (HSC). Since fibrosis represents an important prognostic turning point in the evolution of virtually any liver disease, direct antifibrotic strategies have ever since been sought after. The ideal drug would be expected to impact on several if not all critical steps involved in the initiation and progression of liver diseases. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of complex cholestatic and metabolic liver diseases.

**Figure 1** Failed metabolic homeostasis results in sublethal cell stress, inflammation and fibrosis. In both non-alcoholic fatty liver disease and cholestasis, inadequate metabolic adaptation to substrate overload results in sublethal cell stress or even cell death with release of mediators (eg, cytokines, chemokines, microRNAs), in part as cargo of extracellular vesicles, driving inflammation and fibrosis. The ideal therapeutic strategy would be expected to impact on several if not all critical steps involved in the progression of liver diseases. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of complex cholestatic and metabolic liver diseases.

**Figure 1**

**Therapeutic strategies**

- **Inflammation**
- **Fibrosis**

**Failed metabolic homeostasis**

- (Sub)lethal cell stress, cell death
less pruritus,34 which could be due to the role of this enzyme in metabolism of lipid metabolites linked to the pathogenesis of cholestatic pruritus.35 In male patients with PSC with bile duct stenosis requiring intervention, the PNPLA3 I148M variant may be a risk factor for reduced survival36 while another study found no impact.37 Knockdown/inhibition of PNPLA3 variants is currently receiving considerable attention as novel treatment strategy for NASH.38 Variants of the ABCB4 gene encoding the hepatobiliary phosphatidylinositol phosphate floppase not only confer risk of bile duct injury and cholestatic liver disease by altering bile toxicity,39 but large-scale whole-genome sequencing uncovered a common ABCB4 variant as a general risk factor for elevated aminotransferases and higher impact variants as potential determinants of early-onset gallstone disease, cholestasis of pregnancy, liver cirrhosis and hepatobiliary cancer.40 As pointed out below, ABCB4 expression can be stimulated by a wide range of NR ligands and chaperones can (partly) restore impaired mutant function.39 These examples may demonstrate, how genetic variants initially considered only in a specific context may have more global impact on progression of liver diseases irrespective of their specific aetiology.

BAs have emerged as important pathogenic factors and therapeutic targets in both cholestatic and metabolic liver diseases.4 13 41 Since BAs are potentially cytotoxic and proinflammatory at higher pathophysiological concentrations it is important to maintain their homoeostasis by controlling BA transport and metabolism (figure 2).13 Besides their well-established role in dietary lipid absorption, BAs have recently been recognised to act as hormone-like signalling molecules that serve as ligands for NRs such as the farnesoid X receptor (FXR)/CAR/NR1I4) as main NR for BAs.42–44 In addition to FXR also other NRs such as the pregnane X receptor (PXR/NR1I2), the constitutive androstane receptor (CAR/NR1I3) and the vitamin D receptor (NR1I1) are activated via certain BAs.45 Through these NRs BA control their own transport and metabolism, lipid and glucose metabolism as well as innate/adaptive immunity.41 Additional critical NRs for the control of metabolism include peroxisome proliferator-activated receptors (PPARs) α, γ and δ as well as thyroid hormone receptor (THR) β. Another key BA receptor is the Takeda G protein-coupled receptor TGR5 (GP-BAR or M-BAR) a G-protein coupled receptor (GPCR).46 In contrast to NRs, GPCRs are localised at the cell membrane and cellular BA uptake/transport is not required for the activation of these receptors. Initial studies uncovered a key role of TGR5 in mediating immunosuppressive effects of BAs on macrophages.46 Moreover, TGR5 has an important role in regulating energy expenditure and lipid metabolism,47 again highlighting the potential role of BAs as key regulators of immunometabolism. Impaired TGR5 expression and signalling may contribute to the pathogenesis of cholangiopathies such as PBC and PSC, since TGR5 also protects cholangiocytes by stimulating bicarbonate secretion.48 49 However, persistent stimulation of TGR5 may predispose to

Figure 2  Therapeutic strategies along the enterohepatic and cholehepatic bile acid (BA) circulation. After hepatic synthesis via cytochrome P450 7A1 (CYP7A1) and excretion into bile through the bile salt export pump (BSEP/ABCB11) BAs undergo an enterohepatic circulation, that is, they are reabsorbed in the ileum by apical sodium-dependent bile acid transporter (ASBT/SLC10A2) and transported back to the liver through portal blood where hepatic reuptake of conjugated BAs is mediated via sodium/taurocholate cotransporting polypeptide (NTCP/SLC10A1) and organic anion transporting polypeptides (OATPs) for unconjugated BAs (not shown). In hepatocytes, farnesoid-X receptor (FXR) induces the transcriptional repressor SHP which in turn inhibits CYP7A1 (BA synthesis) and NTCP transcription (BA uptake). FXR induces BSEP, phospholipid export pump/flipase (MDR3/ABCB4; Mdr2 in mice) and cholesterol export pump (ABCG5/8). At the basolateral membrane organic solute transporter (OST) αβ heterodimer for BA efflux into portal blood. Intestinal FXR via DiET1 induces fibroblast growth factor (FGF) 19, which circulates to the liver and binds to its receptor FGFR4, subsequently inhibiting BA synthesis. Gut microbiota deconjugate and dehydroxylate primary BAs into secondary BAs. Enterohepatic drugs acting within the gut-liver axis: (non-)steroidal FXR agonists (eg, obeticholic acid) and FGF19 mimetics. Cholehepatic drugs, such as nor-ursodeoxycholic acid (norUDCA), undergo cholehepatic shunting between hepatocytes and cholangiocytes, thereby cutting short the enterohepatic circulation. Transport blockers: ASBT inhibitors and BA sequestrants as well as NTCP inhibitors, prevent intestinal or hepatic BA reuptake. TJ, tight junction.
Recent advances in clinical practice

![Diagram](Image)

**Figure 3** Nuclear receptors as therapeutic targets regulating metabolism and inflammation. Hepatocyte, left panel: farnesoid X receptor (FXR) represses hepatic bile acid (BA) uptake sodium/taurocholate cotransporting polypeptide (NTCP) and BA synthesis cytochrome P450 7A1 (CYP7A1) via induction of the transcriptional repressor SHP (not shown). Moreover intestine-derived fibroblast growth factor (FGF) 19 (binding to the FGF4/βKlotho dimer) also downregulates CYP7A1 expression. Conversely, FXR promotes biliary excretion of BAs, phospholipids (PL) and bilirubin via induction of canalicular bile salt export pump (BSEP), multidrug resistant protein 3 (MRD3) and multidrug resistance-related protein 2 (MRP2), respectively (centre), and also facilitates BA elimination via alternative basolateral BA transporter such as organic solute transporter (OST) (not shown). BA detoxification by phase 1 and 2 enzymes is stimulated through FXR and peroxisome proliferator-activated receptor (PPAR)α. PPARα stimulates phospholipid secretion (via MRD3), thus counteracting intrinsic bile toxicity. Right panel: FXR as well as PPARα and δ reduce inflammation via suppression of NFκB. FXR and PPARα improve hepatic insulin sensitivity. FGF19, FGF21, and thyroid hormone receptor beta (THRβ) suppress de novo lipogenesis, while PPARα and δ stimulate β-oxidation. In cholangiocytes (lower panel), activation of FXR, vitamin D receptor (VDR) and glucocorticoid receptor (GR) exert cholangioprotective effects via upregulation of vasoactive intestinal polypeptide receptor 1 (VPAC1), anion exchanger (AE) 2 and cathelicidin. Activation of PPARγ in cholangiocytes reduces vascular cell adhesion molecule (VCAM-1) expression, thereby counteracting reactive cholangiocyte phenotype. Anti-fibrotic effects of nuclear receptors (NRs) in hepatic stellate cells (HSCs, far right panel): PPARα and γ and VDR reduce expression of profibrogenic genes such as alpha smooth muscle actin (αSMA), Collagen 1α1 (Col1α1), TIMP1, platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ) and angiopoietin-2 (ANG2). Furthermore, NRs reduce migration, proliferation as well as trans-differentiation of HSC into myofibroblasts. Anti-inflammatory effects of NRs are related to their activation in immune cells such as macrophages and Kupffer cells (as well as adaptive immune cells, not shown). Activation of FGF21, PPARα, γ, δ and VDR reduce expression of proinflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin 1 beta (IL1β) (lower right panel). Cenicriviroc (CVC) an antagonist for C-C chemokine receptor type 2 and 5 (CCR2/5) on macrophages, Kupffer cells and HSCs exerts anti-inflammatory and anti-fibrotic effects. As result of FGF21 and PPARγ activation in adipocytes, insulin sensitivity is increased (lower left panel).

Changes in gut microbiota (dysbiosis) may play a key role in the pathogenesis of NAFLD/NASH and cholestasis32-34 and may also impact on BA composition and signalling.51-53 Conversely, BAs and FXR ligands alter intestinal microbiota which may add to their therapeutic effects in both entities.53-55 Specific gut pathobionts such as Klebsiella pneumoniae may disrupt the intestinal epithelial barrier and initiate a hepatic T helper 17 cell immune response in PSC.56 Interestingly, NAFLD pathogenesis has been linked to high-alcohol-producing K. pneumoniae.55 Treating dysbiosis with restoration of its immunological and metabolic function holds much promise in both disease areas. Various absorbable/systemic and non-absorbable antibiotics may act via modulation of gut microbiota and have shown to improve liver biochemistry in PSC, with vancomycin as one of the most promising agents.19 Probiotics have been rather disappointing in treatment of NASH19 and cholestatic disorders such as PSC,61 but faecal microbiota transplantation from lean donors improves insulin resistance in individuals with metabolic syndrome56 and has shown first promising results in PSC.63 Importantly, gut microbiota may not only serve as a trigger of liver injury but may also have protective actions. As such total elimination of gallstone formation through changes in gallbladder motility and promotes proliferation of cholangiocellular carcinoma (CCC) cells and polycystic cholangiocytes which overexpress TGR5, thus raising safety concerns for clinical development of TGR5 agonists.50 Therefore, depending on the clinical context and the underlying disease either activation or inhibition of TGR5 may have beneficial effects.

BAs undergo an enterohepatic circulation (4–12 times per day) and are effectively conserved by reabsorption in the terminal ileum (figure 2); thus only 3%–5% BAs are lost via stool and need to be replaced by daily BA synthesis.13 There is an intensive bidirectional interaction between BAs and intestinal microbiota.51 On one hand, BAs control and modify the composition of gut bacteria through their detergent and signalling properties while on the other hand BAs are deconjugated and metabolised to secondary BAs by the intestinal microbiota.71
intestinal microbiome in germ-free mice has been shown to aggravate liver injury in mouse models of liver fibrosis and PSC. 64 65

These specific examples may emphasise the multiple, partly unexpected mechanistic similarities and shared principles between metabolic and cholestatic liver diseases, which have cross-fertilised our pathogenetic understanding for both areas with imminent implications for the development of joint therapeutic strategies.

NUCLEAR RECEPTOR PATHWAYS AS A NEW THERAPEUTIC FRONTIER

The NR superfamily is the largest group of transcriptional regulators and consists of 48 members in humans. 51 Ligands include both endogenous and exogenous molecules such as hormones, fatty acids, BAs, other intermediary products of metabolism, drugs and toxins. 23 27 NRs typically induce transcriptional programmes involved in metabolism or transport of the ligand, thus providing a feedback mechanism to maintain cellular homeostasis. 3 25 Many of the recently developed drugs for cholestatic and metabolic liver diseases are high affinity ligands for these NRs (in the nanomolar to low micromolar range), thus avoiding the toxicity otherwise associated with administration of their natural ligands. Thus, NRs such as FXR, PPARs and THR have become key therapeutic targets for the development of new drugs for cholestatic and fatty liver diseases (table 1, figure 3). Moreover, xenobiotic sensors such as CAR and PXR might be interesting future pharmacological targets since they also have a critical role in BA and lipid metabolism. 26

In PBC, UDCA is used as first-line treatment, 2 66 67 but 30%–50% of patients respond insufficiently (based on biochemical criteria) and require a second-line therapy with FXR ligands with the approved drug obeticholic acid (OCA) 68 69 • off-label use of PPAR ligands such as fibrates 70 • or glucocorticoid receptor (GR)-ligands such as budesonide 71 which is mainly used in the context overlap syndromes. 66 67 72 NR targeted therapies may be viewed as immunomodulatory drugs targeting both biliary homeostasis and inflammation/immunity (figure 3) which makes them highly attractive targets for immune-mediated cholestatic disorders such as PBC and PSC where both aspects may contribute to disease pathogenesis and progression. Even budesonide may have more than anti-inflammatory and immunosuppressive effects via GR since recent data indicate that it also controls bile detoxification (via PXR) and bicarbonate secretion. 73 Interestingly biologics in this presumably autoimmune disorder have been quite disappointing so far, although several appealing immunomodulatory concepts (eg, Janus Kinase (JAK)1/2 inhibitors (baricitinib), anti-interleukin-17, etrasimod (S1P receptor 1,4,5 modulator), anti-CX3CL1/anti-Fractalkine are still tested in ongoing trials. 74 75 76

In PSC no established drug treatment exists so far and we face the challenges of the high malignancy risk and its association with inflammatory bowel disease. 77 Intriguingly, NR could not only address hepato-biliary homeostasis but also gut inflammation and microbiota in PSC. 76 As such NR (FXR, PPAR)-targeted therapies could even represent a one stop shopping for both liver and gut.

In NASH clinical trials with OCA (targeting FXR) 77 78 and pioglitazone (targeting PPARγ) 79–82 have already demonstrated efficacy of NRs ligands through control of lipid metabolism, inflammation and fibrosis 83 (table 1). Another promising emerging NR target is THR which now can be targeted with liver specific THR-β ligands (table 1). 84

Farnesoid X receptor

As major intracellular BA receptor and key regulator of BA homeostasis, 42–44 as well as lipid and glucose metabolism, 41 FXR has become a central therapeutic target for cholestatic and fatty liver diseases. Moreover, FXR modulates liver regeneration, carcinogenesis, inflammation and intestinal microbiota. 12 13 41 45 While the effects on intestinal integrity and microbiota are mediated via FXR regulated antimicrobial peptides and tight junction proteins, the anti-inflammatory effects of FXR are mainly due to nuclear factor kappa B (NFκB) antagonising effects. 85 Mice lacking FXR show severely disturbed BA homeostasis and genetic variants of FXR in humans cause a subtype 5 of severe progressive familial intrahepatic cholestasis, 86 emphasising the key role of FXR in BA homeostasis and pathogenesis of cholestasis. Expression of FXR is also reduced by inflammation and in various cholestatic diseases such as in PBC. 87 Conversely, pharmacological activation of FXR restores BA homeostasis by stimulation of transcription of the bile salt export pump that mediates the rate-limiting step in hepatocellular BA excretion across the canalicular membrane. Together with a reduction of BA uptake systems Na+-taurocholate cotransporting polypeptide (NTCP) and synthesis (CYP7A1) as well as stimulation of alternative basolateral export systems (OSTe/β), this reduces hepatic BA load and alleviates BA-mediated cellular stress in cholestasis, 88 which makes FXR an attractive key target for treatment of cholestasis (figures 2 and 3).

In NAFLD BA-activated FXR pathways are involved in the regulation of hepatic lipogenesis and lipoprotein metabolism, gluconeogenesis, glycerogen synthesis and insulin sensitivity. 12 27 41 88 (figure 3). In addition to the physiological hormonal function of BAs in the regulation of lipid and glucose metabolism there is also convincing evidence for disturbed BA homeostasis in NASH. With increasing severity of NASH and fibrosis, BA levels tend to increase and the composition of BAs changes, which may partly result from insulin resistance, 89 impaired hepatobiliary excretory function 18–20 and altered microbial BA metabolism caused by NASH-associated dysbiosis. 35 Despite increased BA levels, FXR and FGF19 signalling is impaired, resulting in increased BA synthesis 90 91 and BA toxicity could contribute to the hepatocellular injury and even carcinogenesis in NASH. 1 12 92 Thus, restoration of FXR signalling and BA and lipid homeostasis may explain at least part of the therapeutic effects of FXR ligands in NAFLD/NASH. In addition, broader anti-inflammatory and antifibrotic effects as well as improved endothelial function mediated by FXR may also contribute. 93

Obeticholic acid as first in class steroidal FXR agonist

OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand. 94 In patients with PBC, OCA as monotherapy or add-on therapy to UDCA in those with insufficient biochemical response, improved biochemical markers of cholestasis 68 69 93 96 and has been conditionally approved as second-line therapy for PBC by the US Food and Drug Administration (FDA) and European Medicines Agency. 66 67 In line with the beneficial effects of OCA in PBC, encouraging results were also observed in patients with PSC 97 (table 1). The main side effect in PBC and PSC was dose-dependent pruritus. Although long-term efficacy of OCA on biochemical parameters and stabilisation of inflammation and fibrosis in PBC has been demonstrated as extension of the phase 3 registration trial up to 5 years, 99 97 a benefit for ‘hard’ clinical endpoints still needs to be demonstrated (table 1). Real world data confirmed the efficacy
Recent advances in clinical practice

### Table 1: Novel therapeutic approaches for both cholestatic disorders and NASH—key clinical trials

<table>
<thead>
<tr>
<th>Compound class</th>
<th>Cholestatic</th>
<th>NASH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steroidal FXR agonist</td>
<td><em>Obeticholic acid (OCA)</em>:</td>
<td><em>Obeticholic acid (OCA)</em>:</td>
</tr>
<tr>
<td></td>
<td>► POISE (phase 3)104: patients with PBC with insufficient biochemical response or intolerance to UDCA showed improvement of ALP and other liver enzymes when treated with 5–10 mg (up titration) or 10 mg OCA for 12 months. Total bilirubin concentrations stabilised. Side effects: pruritus, fatigue, increased LDL cholesterol. Long-term data (up to 5 years) confirm phase 3 efficacy and safety data, 4% withdrew treatment.104</td>
<td>► FLINT (phase 2b)172: 25 mg OCA for 18 months improved NAFLD activity score (predefined primary endpoint) and its individual components, but did not result in significantly higher NASH resolution (22 vs 13% compared with placebo); however, a higher proportion of patients (35 vs 19%) showed improved fibrosis (by at least one stage). Side effects: pruritus and hypercholesterolaemia (increased LDL cholesterol, reduced HDL cholesterol).</td>
</tr>
<tr>
<td></td>
<td>► COBALT (NCT02308111): ongoing phase 4 study, evaluates long-term clinical outcomes in patients with PBC.</td>
<td>► REGENERATE (phase 3)172: 18-month interim analysis in patients with non-cirrhotic NASH (F2 or F3) showed that 25 mg OCA significantly improved fibrosis by &gt;1 stage (23% vs 12% under placebo) but not NASH (12% vs 8%, n.s.).</td>
</tr>
<tr>
<td></td>
<td>► AESOP (phase 2)144: in patients with PSC, ALP was significantly reduced by 5–10 mg OCA but not by 1.5–3 mg OCA over 24 weeks.</td>
<td>► REVERSE (NCT03493254): ongoing phase 3 study evaluating whether OCA improves in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.</td>
</tr>
<tr>
<td>Non-steroidal FXR agonists</td>
<td><em>Cilofexor</em>:</td>
<td><em>Cilofexor</em>:</td>
</tr>
<tr>
<td></td>
<td>► PSC (phase 2)110: 12 weeks of cilofexor improved serum ALP, γGT, AST, ALT, bile acid and C4 levels. No pruritus (even trend for improvement).</td>
<td>► NASH with F1-F3 (phase 2)106: 24 weeks of cilofexor treatment reduced hepatic fat content (MRI-PDFF) and serum γGT (but not ALT and AST). No significant changes in lipid parameters. Side effects: dose-dependent pruritus.</td>
</tr>
<tr>
<td></td>
<td>► PRIMIS (NCT03390120): ongoing phase 3 evaluating whether cilofexor reduces the risk of fibrosis progression in non-cirrhotic patients with PSC.</td>
<td>► ATLAS (phase 2)105: cilofexor, ASK-1 inhibitor selonsertib and ACC inhibitor firsocostat tested in patients with advanced fibrosis (F3-F4) due to NASH; primary endpoint (≥1 stage improvement in fibrosis without worsening of NASH) was not reached in any of the monotherapy groups; selonsertib monotherapy group was discontinued following termination of the STELLAR trials142. Combination of firsocostat and cilofexor over 48 weeks did not improve fibrosis ≥1 stage without worsening of NASH, but significantly higher proportions had a ≥2-point NAS reduction with improvements in steatosis, lobular inflammation and ballooning; significant improvements in ALT, AST, bilirubin, bile acids, CK18, insulin, eGFR, ELF score, and liver stiffness.</td>
</tr>
<tr>
<td></td>
<td>► PBC (phase 2)137: improvement of serum ALP, γGT, AST, ALT, bile acid and C4 levels by 12 weeks. Side effects: pruritus.</td>
<td>► FLIGHT-FXR (phase 2)116: at 12 weeks interim analysis tropifexor reduced ALT and γGT levels as well as liver fat content (MRI-PDFF). After 48 weeks no significant differences in histological improvement of NASH or fibrosis (F2-F3) compared with placebo were seen, but significant reductions of collagen proportional area. Side effects: pruritus; increased serum levels of LDL-cholesterol and decreased HDL-cholesterol.</td>
</tr>
<tr>
<td>Tropifexor:</td>
<td>► PBC (phase 2)112: 4 weeks of tropifexor treatment showed dose dependent improvement of γGT and ALT (but not ALP). Side effects: pruritus.</td>
<td>► NASH with F1-F3 (phase 2)106: at 12 weeks tropifexor reduced hepatic fat content (MRI-PDFF) and decreased HDL cholesterol, decrease in LDL cholesterol, pruritus.</td>
</tr>
<tr>
<td></td>
<td>► TROJAN (NCT02680761): dose titration study.</td>
<td></td>
</tr>
<tr>
<td>FGF19 mimetic</td>
<td><em>Aldafermin/NGM282</em>:</td>
<td><em>Aldafermin/NGM282</em>:</td>
</tr>
<tr>
<td></td>
<td>► PBC (phase 2)137: 28 days of aldafermin slightly improved liver enzymes. Side effects: gastrointestinal symptoms (mostly diarrhoea).</td>
<td>► NASH with F2/F3 (phase 2): improved hepatic fat content (MRI-PDFF), serum aminotransferase levels and non-invasive fibrosis markers (pro-C3) after 24 weeks (1 mg)138 in line with a 12-week study testing higher doses (3 and 6 mg)139, histological improvement of fibrosis or NASH did not reach statistical significance136 despite encouraging signals of a 12-week open label study136. Side effects: dose-dependent diarrhea, abdominal pain, nausea, increases in LDL-cholesterol which could be managed with statins136 138 139.</td>
</tr>
<tr>
<td></td>
<td>► PSC (phase 2)137: at 12 weeks improved non-invasive markers of hepatic fibrosis, but not ALP. Side effects: gastrointestinal symptoms.</td>
<td></td>
</tr>
<tr>
<td>PPARα agonists</td>
<td><em>Bezafibrate</em>:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>► BEZURSO (phase 3)106: bezafibrate 400 mg/day over 24 months resulted in complete biochemical response (defined as normalisation of hepatic serum biochemistry including ALP, aminotransferases, albumin, bilirubin and prothrombin index) in 31% of patients with PBC with an incomplete response to UDCA vs 0% on placebo; 67% normalised ALP, also improved pruritus and liver stiffness. Side effects: increases in serum creatinine, myalgia and hepatotoxicity (ALT&gt;5 x ULN).</td>
<td>No larger clinical trials in this indication.</td>
</tr>
<tr>
<td>PPARγ agonist</td>
<td>No systematic clinical trials in this indication.</td>
<td></td>
</tr>
<tr>
<td>Pioglitazone:</td>
<td>► PIVENS (phase 3)179: non-diabetics with NASH; 96 weeks of treatment with pioglitazone improved serum transaminases, hepatic steatosis and inflammation, while no significant improvement of fibrosis and NASH was observed. Side effects: weight gain.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>► In NASH patients with T2DM 36 months treatment was associated with resolution of NASH and improvement in individual histological scores, including fibrosis; improved hepatic fat content (MR-PDFF) and adipose tissue, hepatic and muscle insulin sensitivity. Side effects: weight gain80.</td>
<td></td>
</tr>
</tbody>
</table>

Continued
Table 1  
Continued

<table>
<thead>
<tr>
<th>Compound class</th>
<th>Cholestasis</th>
<th>NASH</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPARα agonist</td>
<td>Seladelpar:</td>
<td></td>
</tr>
</tbody>
</table>
|                | 1. PBC (phase 2a) [160]: 12 weeks of seladelpar treatment improved ALP in patients with PBC with inadequate response to UDCA (normalisation in five patients treated for full 12 weeks), but three patients developed fully reversible, asymptomatic grade 3 ALT increases (one on 50 mg, two on 200 mg), study was terminated after 41 patients were randomised.  
2. ENHANCE (NCT03602560): Ongoing phase 3 study evaluating the safety and efficacy of lower doses (5 or 10 mg) of seladelpar in patients with PBC with inadequate response or intolerant to UDCA. By 3 months (interim analysis) 10 mg seladelpar normalised ALP levels in 27% of patients. Improvement of pruritus [164].  
3. PSC (phase 2; NCT04024813)—ongoing. |
|                | Elafibranor:  |
|                | 1. GOLDEN (phase 3): resolution of NASH (F0-F3) without fibrosis worsening, based on a modified definition, while the predefined end point was not met; improved cardiometabolic risk profile.  
2. RESOLVE-IT [171]: phase 3 study in biopsy-proven NASH patients (NAS ≥4; F1-F3). 72 weeks of elafibranor did not achieve the primary endpoint NASH resolution without worsening fibrosis (19% of patients in the treatment arm compared with 15% of patients in the placebo group; n.s.). |
| PPARα/δ agonist | Saroglitazar:  |
|                | PBC (phase 3, open label) [165]: 16 weeks of saroglitazar (in addition to UDCA) improved serum ALP (primary endpoint) and γGT levels. |
|                | Elafibranor:  |
|                | PBC (Phase 2a) [166]: at 12 weeks elafibranor improved serum ALP, ALT, γGT, bilirubin, cholesterol, triglycerides and CRP in patients with PBC without adequate response or intolerance to UDCA. A potential antipruritic effect was also observed.  
2. ELATIVE (NCT04526665), phase 3 study evaluating the effect of 80 mg elafibranor in patients with PBC not responding to UDCA. |
| FGF21 mimetics | No clinical trials in this indication. |
| THR (α1) agonists | Resmetirom (MGL-3796):  |
|                | 1. NASH with F1-3 (phase 2) [167]: reduced hepatic fat content (MRI-PDFF) and liver transaminases after 16 weeks; increased serum levels of adiponectin and improved lipid profile (reduction in LDL cholesterol and triglycerides, increase in HDL cholesterol). Side effects: diarrhoea, nausea.  
2. Efruxifermin (EFX):  |
|                | NASH with F1-3 (phase 2a) [172]: Over 16 weeks improved hepatic fat content (MRI-PDFF), serum triglycerides with increase in HDL cholesterol and no increase in LDL cholesterol. In patients ≥30% reduction in hepatic fat undergoing end-of-treatment biopsies, 85% had a ≥2-point reduction in NAS, 78% had a ≥2-point reduction in NAS without worsening of fibrosis, 48% had ≥1 stage improvement in fibrosis without NASH worsening; 28% had both NASH resolution and fibrosis improvement (no placebo control group with histology). Gastrointestinal side effects.  
3. Pegbelfermin:  |
|                | NASH with F1-3 (phase 2a) [174]: reduced hepatic fat content (MRI-PDFF) after 36 weeks; histological improvement (≥2 point NAS reduction, NASH resolution); significant reduction of liver enzymes, LDL cholesterol, triglycerides and lipoprotein(a). N-terminal type III collagen propeptide (non-invasive fibrosis marker) was reduced. Side effects: diarrhoea, nausea.  
4. Resmetirom-NASH (NCT03900429):  
(a) Open label extension study for additional 36 weeks demonstrated further improvement of liver fat and liver enzymes [175].  
(b) MAESTRO-NASH (NCT03900429): ongoing phase 3 study to evaluate the efficacy and safety of resmetirom in NASH patients with fibrosis (F1-3); primary endpoint: resolution of NASH without worsening of fibrosis and prevention of progression to cirrhosis or advanced liver disease.  
5. VCK2809:  |
|                | NASH (phase 2) [176]: VK2809 therapy for 12 weeks improved liver fat content (MRI-PDFF).  
6. VOYAGE (NCT04173065) — ongoing phase 2 evaluating the impact on liver fat content (MRI-PDFF); primary outcome) at week 12 and NASH CRN fibrosis score (secondary outcome) at week 52. |

---

Continued
and safety of OCA in PBC with lower efficacy and reduced tolerability in patients with cirrhosis. Notably, use of OCA was associated with an increase in hepatic decompensation in patients with compensated PBC cirrhosis, which led to an update of the label for use in patients with decompensated cirrhosis, a prior decompensation event or with compensated cirrhosis and evidence of portal hypertension.

A phase 2a study in patients with type 2 diabetes and NAFLD showed improved insulin sensitivity as well as gamma glutamyl transferase (γGT) and alanine amino transferase (ALT) by OCA. A subsequent phase 2b trial in patients with NASH revealed an improvement in the NAS score as predefined primary endpoint. Compared with placebo, no improvement was observed with placebo. NorUDCA was safe and well tolerated.

In addition to OCA, several non-steroidal FXR ligands with even higher affinity for FXR have been developed. Some of which have already been tested in phase 2 clinical studies for the treatment of PBC, PSC and NASH (table 1). In contrast to steroidal FXR agonists, non-steroidal FXR ligands no longer have a BA structure and therefore, may have different pharmacokinetic profiles, efficacy and safety profiles.

Non-steroidal FXR agonists—the next generation of FXR agonists

In addition to OCA, several non-steroidal FXR ligands with even higher affinity for FXR have been developed. Some of which have already been tested in phase 2 clinical studies for the treatment of PBC, PSC and NASH (table 1). In contrast to steroidal FXR agonists, non-steroidal FXR ligands no longer have a BA structure and therefore, may have different pharmacokinetic profiles, efficacy and safety profiles.

Some of these agonists may operate as gut-preferential FXR ligands, with shorter hepatic and limited systemic exposure which has raised expectations to limit prototypic side effects such as dyslipidaemia and pruritus. In patients with PSC the non-steroidal FXR agonist cilofexor improved cholestatic liver enzymes and non-invasive markers of liver fibrosis without aggravation of pruritus. Similarly, cilofexor improved liver enzymes in patients with PBC, but pruritus was observed in this study.

The precursor compound of cilofexor, PX-104, improved insulin sensitivity and liver enzymes in patients with non-diabetic NAFLD. Cilofexor reduced hepatic fat content (MR-PDFF) and serum γGT in patients with NASH, again dose-dependent pruritus was noted as a side effect (table 1). Interestingly, no significant changes in lipid parameters were observed with cilofexor in this study. Cilofexor has also been investigated in combination with the Acetyl-CoA carboxylase (ACC) inhibitor firsocostat and/or semaglutide (GLP-IRA) (table 1).

Tropifexor, another highly potent non-steroidal FXR agonist, has been explored in a phase 2 clinical trial which showed improvement of liver enzymes and hepatic fat content (table 1). Serum levels of low density lipoprotein (LDL)-cholesterol were moderately increased while high density lipoprotein (HDL)-cholesterol was reduced, and pruritus was reported as side effect, again demonstrating that non-steroidal FXR ligands may have a side effect profile similar to steroidal FXR ligands in line with experimental data.

Tropifexor reduced γGT (but not alkaline phosphatase (ALP)) in patients with PBC and pruritus was noted. The absence of ALP reduction might be explained by potent FXR-related activation of ALP transcription through the high affinity ligand tropifexor. Tropifexor has also been tested in combination with cenicriviroc (CCR2/5 blocker, see below) in patients with NASH and F2/F3 fibrosis (TANDEM, NCT03517540). Another study explores the combination of tropifexor and licogliflozin (a dual inhibitor of both SGLT1 and SGLT2) in NASH (ELIVATE, NCT04065841).

In a recent smaller phase 1b study the non-steroidal, fexeramine-derived FXR agonist MET409 improved fat content (MRI-proton density fat fraction (PDFF)) over 12 weeks and is further evaluated alone or in combination with empagliflozin (SGLT2 inhibitor) in patients with both NASH and type 2 diabetes (NCT04702490). Dose-dependent pruritus, increases in LDL cholesterol, fasting glucose and transient ALT elevations were observed with MET409, which could be partly overcome...
by choosing a lower dose which still effectively reduced liver fat.\textsuperscript{113} Some non-steroidal FXR agonists may act exclusively in the gut, effects which may be mediated largely by stimulation of intestinal FGF19 expression.\textsuperscript{114} As such, the intestine-restricted FXR agonist fexaramine, reduced weight gain, decreased insulin resistance and improved hepatic steatosis in mice.\textsuperscript{115} Interestingly, an opposing strategy with intestinal FXR antagonism through specific BA species (eg, taurine or glycine-β-muricholic acid) also has beneficial effects against hepatic steatosis in mice; these effects were mediated through inhibition of intestinal FXR-dependent ceramide production which contributes to obesity and hepatic steatosis.\textsuperscript{116 117} However, such beneficial effects of FXR antagonism may be restricted to the intestine, since inhibition of hepatic FXR gives rise to cholestasis, steatosis or even liver cancer as suggested from FXR knockout studies in mice.\textsuperscript{85}

UDCA—FXR agonist or antagonist? UDCA can be viewed as the first available ‘enterohepatic drug’ circulating with the endogenous BA pool enriched by UDCA.\textsuperscript{118} UDCA is used for treatment of a broad range of cholestatic disorders with proven survival benefit as first-line treatment of PBC.\textsuperscript{2} In addition to its cytoprotective properties, UDCA acts as a secretagogue in hepatocytes and cholangiocytes, stimulating the vesicular targeting of transporters to the canalicular membrane.\textsuperscript{2} UDCA is a weak FXR agonist in vitro\textsuperscript{119} which competes with stronger FXR-agonistic signalling of endogenous BAs in man thus acting as weak agonistic antagonist.\textsuperscript{120} UDCA had only limited therapeutic efficacy in NASH in larger randomised controlled studies,\textsuperscript{121–124} although improvement of hepatic insulin resistance was observed in one high-dose study.\textsuperscript{123} Short-term, high-dose UDCA (given prior to bariatric surgery to morbidly obese patients with NAFLD), showed FXR-agonistic effects in vivo, thereby stimulating BA synthesis and inducing lipid accumulation in liver as well as visceral white adipose tissue.\textsuperscript{120} Although enhanced triglyceride (TG) storage could be viewed beneficial as reflection of lipid partitioning counteracting lipotoxicity, it may be counterintuitive to stimulate both BA and TG synthesis as two deranged key pathways in the pathogenesis of NASH. In line with these findings, UDCA is no longer recommended for treatment of NAFLD/NASH.\textsuperscript{125}

Fibroblast growth factor 19 FXR stimulates expression of intestinal FGF19 in the terminal ileum, which—after reaching the liver via the portal circulation and binding to FGFR4/βKlotho receptor complex—inhibits hepatic BA synthesis through repression of CYP7A1.\textsuperscript{50 126} FGF19 is also a key regulator of postprandial lipid and glucose metabolism, as reflected by suppression of lipogenesis and glucose-neogenesis, but promotion of fatty acid oxidation and glycogen synthesis.\textsuperscript{50 126} In addition to its role in regulating BA homoeostasis and metabolic pathways (figures 2 and 3), FGF19 also stimulates cell proliferation in the liver and molecular alterations of FGF19-FGFR4 signalling which raises potential concerns for hepatic carcinogenesis, when overstimulated by FXR ligands.\textsuperscript{127} Notably, aberrant FGF19-FGFR4 signalling has been identified in HCC\textsuperscript{,127} but not in CCC where other pathways/genomic alterations including FGFR2 (intrahepatic CCC)\textsuperscript{128} or TP53 and KRAS (PSC-associated extrahepatic/peripheral CCC)\textsuperscript{129} among others are involved. Importantly, non-tumorigenic variants of FGF19, such as M52/M70/NGM282 (aldafermin),\textsuperscript{130 131} have been developed which can be used therapeutically with beneficial effects on metabolism without promoting or perhaps even countering carcinogenesis.\textsuperscript{132 133} The FGF19 mimetic M70/NGM282 improved liver injury in the Mdr2/Abcb4\textsuperscript{−/−} mouse model of sclerosing cholangitis.\textsuperscript{130} Moreover, M52, protected Mdr2/Abcb4\textsuperscript{−/−} and Fxr\textsuperscript{−/−} mice from spontaneous hepatic fibrosis, cellular proliferation and HCC formation.\textsuperscript{134} In patients with PBC with insufficient response to UDCA NGM282/aldafermin mildly improved cholestatic liver enzymes, but mainly gastrointestinal side effects such as diarrhoea, abdominal pain and nausea (but not pruritus) were observed\textsuperscript{131} (table 1). Interestingly, NGM282/aldafermin improved non-invasive serum markers of hepatic fibrosis without reducing cholestatic liver enzymes such as ALP in patients with PSC,\textsuperscript{135} possibly reflecting direct anti-inflammatory and antifibrotic actions. Whether NGM282/aldafermin-related anti-inflammatory and antifibrotic effects may reduce the risk of malignancies in PSC remains open.

FGF19 is also an attractive therapeutic target in NASH (table 1) where NGM282/aldafermin, significantly reduced hepatocellular fat content, serum aminotransferase levels and non-invasive fibrosis markers while histological improvement of fibrosis or resolution of NASH did not reach statistical significance after 24 weeks of treatment.\textsuperscript{136} Interestingly, enrichment of Veillonella, a BA-sensitive bacteria whose enrichment is enabled by NGM282/aldafermin, may be a marker for therapeutic response.\textsuperscript{137} Side effects of NGM282 are mostly of gastrointestinal origin but also include increases in LDL-cholesterol,\textsuperscript{138} which can be managed by statins.\textsuperscript{139} These findings emphasise that FXR/FGF-19-mediated suppression of BA synthesis will result in increased hepatocellular cholesterol levels with subsequent downregulation of LDL-receptor and increased serum cholesterol levels.\textsuperscript{88} This is an important consideration for any FXR-pathway targeted therapy in NASH and associated cardiovascular risk.\textsuperscript{7}

Peroxisome proliferator-activated receptors PPARs are a group of NRs that fine tune lipid and glucose metabolism and regulate inflammation and fibrosis.\textsuperscript{140 141} The three isoforms, PPARα, PPARγ and PPARδ (also known as δ), are expressed in different parenchymal and non-parenchymal liver cell compartments, making them highly attractive targets for therapy of metabolic\textsuperscript{142} and cholestatic liver diseases.\textsuperscript{143} Various drugs target PPARα (fibrates), PPARγ (thiazolidinediones/glitazones), PPARδ (seldapelar) or simultaneously two PPAR isoforms (PPARα/γ—glitazars and PPARδ—elafibranor). Recently more broadly acting pan-PPAR ligands such as lanifibranor have been propagated. Bezafibrate is a strong and predominant PPARα ligand with activity for other isoforms and therefore is sometimes also referred to as pan PPAR ligand.\textsuperscript{140 141}

PPAR alpha

Despite their key role in lipid metabolism and management of dyslipidaemia,\textsuperscript{140} PPARα ligands (fibrates) did not show convincing efficacy in NASH in smaller pilot studies.\textsuperscript{144} However, several studies have demonstrated beneficial effects of fibrates (bezafibrate and fenofibrate) in cholestasis which seem to be mediated by repression of BA synthesis, stimulation of phospholipid excretion (counteracting intrinsic BA toxicity on bile ducts) and anti-inflammatory effects (via suppression of NFκB signalling).\textsuperscript{143} Bezafibrate 400 mg/day over 24-month resulted in complete biochemical response in 31% of patients with PBC with an incomplete response to UDCA\textsuperscript{70} (table 1). In 67% of patients even complete normalisation of alkaline phosphate was observed, which is more rarely obtained with FXR

Trauner M, Fuchs CD. Gut 2021;0:1–16. doi:10.1136/gutjnl-2021-324305

Gut: first published as 10.1136/gutjnl-2021-324305 on 6 October 2021. Downloaded from http://gut.bmj.com/ on November 25, 2021 by guest. Protected by copyright.
Recent advances in clinical practice

ligands (7% with OCA)\(^9\) or budesonide (35%).\(^7\) Importantly, pruritus, liver stiffness and prognostic scores of PBC improved, in line with other recent studies confirming the positive effects on pruritus\(^145\) and long-term outcomes from the vast Japanese experience.\(^147\) Side effects include increases in serum creatinine, myalgia and hepatotoxicity (ALT elevations). Increases in creatinine appear to be a pharmacodynamic effect without nephropathy\(^148\) and and usually do not require cessation of treatment. Bezafibrate is currently not approved for the treatment of cholestatic liver diseases and thus used off-label when prescribed to patients with PBC or PSC. Moreover, bezafibrate is not available in the USA, where fenofibrate with a narrower PPAR\(\alpha\)-spectrum could be used since it has also demonstrated beneficial effects in smaller studies.\(^149\)\(^150\) Encouraging first results with fibrates have also been reported in PSC.\(^151\)

### PPAR gamma

In line with their key metabolic effects on insulin sensitivity, glucose and lipid metabolism\(^152\) thiazolidinediones/glitazones (PPAR\(\gamma\) agonists) such as pioglitazone have been shown to improve NASH and fibrosis\(^79\)\(^-\)\(^82\) (table 1). Although so far no licensed drug therapy for NASH exists, they can be used alone or in combination with vitamin E according to current treatment guidelines.\(^125\)\(^153\) Glitazones also have shown beneficial effects in preclinical models of cholestasis by inhibiting bile duct proliferation and fibrosis in a rat model of chronic cholestasis,\(^154\) but they have clinically never been followed systematically except single case reports.\(^155\) In contrast to PPAR\(\alpha\) a direct role for PPAR\(\gamma\) in the regulation of BA metabolism has not yet been reported. However, targeting PPAR\(\gamma\) may of particular interest in inflammatory cholestasis because of its crucial role in attenuation of inflammation-mediated transporter and enzyme changes.\(^156\) These findings suggest unexpected anti-cholestatic actions of classic metabolic drugs, although these mechanisms may not justify repurposing of these drugs for these indications. Notably, the plant extract curcumin, the yellow pigment of the spice turmeric, reduces liver damage, cholangitis and biliary fibrosis in Mdr2/Abcb4\(^{-/-}\) mice by blocking proinflammatory cholangiocyte activation in a PPAR\(\gamma\)-dependent fashion.\(^157\) However, curcumin did not result in significant improvements in cholestasis or symptoms in a recent pilot study in patients with PSC.\(^158\)

### PPAR-\(\delta\)

PPAR-\(\delta\) is ubiquitously expressed and profoundly influences BA and lipid metabolism, as well as inflammation and fibrosis\(^159\) making it an attractive therapeutic target for metabolic and cholestatic liver diseases. However, PPAR-\(\delta\)-triggered mechanisms could promote cancer cell survival and cancer progression, which has raised concerns for their clinical development.\(^159\) Seldelpar is currently the only PPAR\(\delta\) ligand clinically developed for treatment of PBC, PSC and NASH, with the most robust results obtained in PBC so far\(^160\) (table 1). Development of this drug was transiently halted due to safety signals in follow-up biopsies in the NASH programme. After an in-depth investigation and comprehensive safety evaluation, all holds on seldelpar for ongoing clinical studies in were lifted.\(^161\) However, the results in NASH were rather controversial with a disconnection of no significant fat reduction (MR-PDFF) and dose-dependent historiographic improvements which however did not reach statistical significance\(^162\) (table 1).

### Dual PPAR agonists

In addition to agonists for specific isoforms, drugs that activate more than one PPAR have been developed. Dual PPAR\(\alpha/\gamma\) agonists, termed glitazars, improve insulin resistance, dyslipidaemia\(^163\) and fatty liver\(^164\) in rodents. Saroglitazar was shown to improve ALT, liver fat content, insulin resistance and atherogenic dyslipidaemia in patients with NASH\(^165\) with encouraging histological signals.\(^166\) However, it has to be kept in mind that some compounds of this class of drugs were also shown to have cardiovascular and renal side effects.\(^167\) Of note, in patients with PBC with inadequate response to UDCA 16 weeks of saroglitazar treatment improved the primary endpoint ALP.\(^168\)

The dual PPAR\(\alpha/\delta\) agonists elafibrator showed beneficial effects on NASH resolution in a post-hoc analysis (with modified endpoint criteria) of the phase 2b GOLDEN-505 study,\(^169\) but had no significant impact on the main endpoint of NASH resolution without an increase in fibrosis in the phase 3 RESOLVE-IT trial.\(^170\) Elafibrator has also shown first results with improvement of cholestatic liver enzymes in patients with PBC not responding to UDCA\(^171\) (table 1).

In line with preclinical data,\(^172\) the pan PPAR agonist lanifibranor showed encouraging phase 2 data with NASH resolution without worsening of fibrosis over 24 weeks in addition to improved liver enzymes and a beneficial lipid profile with increased HDL cholesterol and reduced triglycerides.\(^173\)

### Fibroblast growth factor 21

FGF21 is another member of the FGF19 subfamily and is physiologically induced mainly in the liver during fasting through a mechanism dependent on PPAR\(\alpha\).\(^174\) FGF21 is a key metabolic messenger regulating glucose and lipid metabolism, insulin sensitivity, energy homeostasis, macronutrient preference and also exerts anti-inflammatory actions via inhibition of c-Jun N-terminal kinase (JNK) and NF-\(\kappa\)B signalling pathways.\(^174\)\(^175\) The interest in therapeutic applications for FGF21 in NASH was stimulated by its ability to correct metabolic dysfunction and decrease body weight in diabetes and obesity.\(^174\) Pegbelfermin, a pegylated FGF21 analogue with prolonged half life,\(^176\) and efruxifermin, a fusion polypeptide of FGF21 with human IgG1 Fc,\(^177\) both reduced hepatic lipid content (MRI-PDFF) in pilot phase 2a studies patients with NASH (table 1). Efruxifermin was also shown to improve markers of fibrosis in F1-F2\(^177\) and F4 patients with NASH with compensated cirrhosis\(^178\) (table 1). Other approaches include humanised bispecific or monoclonal antibodies activating the FGFRI/\(\beta\)-Klotho complex and have been shown to improved liver fat content and serum lipids.\(^175\)

### Thyroid hormone receptor

Thyroid hormones stimulate hepatic fatty acid \(\beta\)-oxidation as well as cholesterol and phospholipid excretion into bile.\(^179\)\(^180\) THR include different isoforms and in liver THR-\(\beta/\beta\) isoform represents 80% of THRs, while 20% are represented by THR-\(\alpha/1\). Selective modulation of THR-\(\beta/1\) allows targeting hepatic genes without cardiac side effects.\(^180\)\(^181\) Numerous studies have linked subclinical hypothyroidism and low thyroid function with NAFLD, NASH and fibrosis as well as cardiovascular mortality.\(^182\)\(^183\) Low-dose thyroid hormone treatment reduced hepatic lipid content in patients with diabetes with NAFLD.\(^184\) Two promising thyromimetic compounds specifically targeting THR-\(\beta/1\) in the liver, resmetirom (MGL-3196) and VK2809 are currently studied and have shown already beneficial effects in phase 2 studies in NASH with additional

---

**Table 1**: Clinical studies of PPAR and other metabolic drugs in cholestasis and NASH.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study Design</th>
<th>NASH Resolution</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezafibrate</td>
<td>Pilot phase 2a</td>
<td>No</td>
<td>Serum creatinine, myalgia</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>Phase 3 RESOLVE-IT</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Elafibrator</td>
<td>Phase 2b GOLDEN-505</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Efruxifermin</td>
<td>Pilot phase 2a</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Pegbelfermin</td>
<td>Pilot phase 2a</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

---

**Table 2**: Dual PPAR agonists in NASH.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study Design</th>
<th>Endpoint Criteria</th>
<th>NASH Resolution</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saroglitazar</td>
<td>Phase 2b</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Elafibrator</td>
<td>Phase 2</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

---

**Table 3**: Metabolic effects of FGF21.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study Design</th>
<th>Hepatic Lipid Content</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegbelfermin</td>
<td>Pilot phase 2a</td>
<td>Reduced</td>
<td>No</td>
</tr>
<tr>
<td>Efruxifermin</td>
<td>Pilot phase 2a</td>
<td>Reduced</td>
<td>No</td>
</tr>
</tbody>
</table>

---

**Table 4**: Thyroid hormone receptor studies in diabetes.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study Design</th>
<th>Hepatic Lipid Content</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resmetirom</td>
<td>Phase 2</td>
<td>Reduced</td>
<td>No</td>
</tr>
<tr>
<td>VK2809</td>
<td>Phase 2</td>
<td>Reduced</td>
<td>No</td>
</tr>
</tbody>
</table>
beneficial impact on associated cardiometabolic risk profiles (table 1).185

PBC is frequently associated with other autoimmune diseases including Hashimoto’s thyroiditis and hypothyroidism may aggravate cholestasis in PBC186 187 since thyroid hormones and THR-β1 regulate BA homeostasis and bile formation180 188 including stimulation of biliary phospholipid excretion via ABCB4.189 190 Notably, defective ABCB4 expression and function result in bile duct injury and various cholestatic syndromes189 emphasising its relevance as therapeutic target. Expression of ABCB4 is also controlled by FXR and PPARα188 190 and the effects of FXR with THR-β1 may be synergetic,189 suggesting that these drugs could be combined in the treatment of cholestatic disorders.

**ENTEROHEPATIC BILE ACID CIRCULATION AS THERAPEUTIC TARGET**

In addition to direct FXR agonists and FGF19 mimetics, pharmacological modulation of BA transport within their enterohepatic circulation may also indirectly alter BA signalling along the FXR-FGF19 axis (figure 2). Blocking ileal BA absorption depletes the body from primary BAs and—as a consequence of the compensatory increase of BA synthesis—also cholesterol, making this an attractive therapeutic approach for both metabolic and cholestatic liver diseases.11 13 BA sequestrants/resins have originally been developed as treatment for hypercholesterolaemia when additional effects on glucose and lipid metabolism such as reductions in hemoglobin A1c (HbA1c) but increases in serum triglycerides—which now can be explained by the role of BA signalling in control of lipid and glucose homeostasis12 21—have already been noted in earlier clinical studies.191 Similar observations have been made in patients with intestinal resections191 and the rationale for apical sodium-dependent bile acid transporter (ASBT) inhibitors is also based on the beneficial effects of surgical interruption of the enterohepatic circulation in patients with paediatric cholestasis.192 Resins bind BAs in the intestinal lumen, but resin-bound BAs are still able to signal through TGR5 which stimulates secretion of GLP1 from enteroendocrine L-cells.193 The high potential of GLP-1 receptor agonists has recently been demonstrated by phase 2 studies with liraglutide194 and semaglutide,195 effects which may be largely mediated by its effects on insulin sensitivity and body weight. Apart from its metabolic effects, GLP-1 has also cholangioprotective effects against apoptosis and attenuating the reactive cholangiocyte phenotype.196 197 The BA sequestrant colesevelam and ASBT inhibitors (lopixibat and A4250) completely reversed liver and bile duct injury in Mdr2/Abcb4−/− mice,198–200 indicating that interruption of enterohepatic circulation of BAs may have therapeutic potential for attenuating cholestatic liver injury beyond their currently explored role in treatment of pruritus.189

Inhibition of ileal BA uptake protects against hepatic steatosis and restored insulin sensitivity in high-fat diet-fed mice, effects which are mediated by a marked shift in hepatic BA composition, with a reduction in hydrophilic, FXR antagonist species and an increase in FXR agonistic BAs.201 However, clinical studies in human NASH with resins and ASBT inhibitors have so far been disappointing.202

Inhibition of NTCP by Myrcludex B (bulevirtide), a small peptide inhibitor originally designed to prevent hepatitis B virus uptake via NTCP may also reduce intrahepatic BA levels.203 However, small molecule inhibitors of NTCP can also prevent HBV infection without interrupting BA uptake.204 Moreover, several drugs such as rosiglitazone, zaflurakast and sulfasalazine inhibit NTCP,205 in a chemical mouse model of sclerosing cholangitis NTCP inhibition by Myrcludex B improved hepatic inflammation and fibrosis.206 However, this therapeutic approach has so far not yet been tested clinically for cholestasis. Notably, genetic absence of NTCP in mice and men results in increased serum levels of unconjugated BAs, but is well tolerated without pruritus, fat malabsorption or liver dysfunction.207 208

norUDCA AS PARADIGM CHOLEHEPATIC DRUG

Nor-ursodeoxycholic acid (norUDCA, recently assigned the new international non-proprietary name norucholic acid) is a side-chain-shortened derivative of UDCA and is resistant to side-chain conjugation with glycine and taurine.209 Consequently, norUDCA—in contrast to its parent compound UDCA—undergoes cholehepatic shunting between cholangiocytes and hepatocytes, which results in the generation of a HCO₃⁻ rich hypercholeresis and high intrahepatic enrichment.209 210 norUDCA has shown anti-cholestatic, anti-inflammatory, immunomodulatory and anti-fibrotic actions in animal models and improves cholestatic liver and bile duct injury in the Mdr2/Abcb4−/− mouse model of sclerosing cholangitis.211–213 Clinically, norUDCA improved biochemical markers of cholestasis in a recent phase 2 clinical trial in PSC irrespective of prior exposure and response to UDCA212 (table 1). Since norUDCA reinforces the HCO₃⁻ umbrella it may also be a therapeutic approach in other cholangiopathies with defective HCO₃⁻ secretion such as PBC.213

In addition to its beneficial effects on the biliary tree, norUDCA has also direct hepatoprotective, anti-inflammatory and anti-fibrotic effects in mouse models of NASH,13 214 215 making it a promising therapeutic agent in NAFLD/NASH with first encouraging data215 (table 1). Notably, norUDCA does not act via FXR or other NRs,213 making it an attractive combination partner for drugs targeting NRs within the enterohepatic circulation (figure 2).

**TARGETING INFLAMMATION AND FIBROSIS VIA CHEMOKINE RECEPTORS CCR2/CCR5**

Macrophages have emerged as essential players in acute and chronic liver injury and in a wide range of liver diseases including NASH216 and more recently also PSC.217 Cenicriviroc (CVC) is a dual CCR2/CCR5 chemokine receptor antagonist that is able to block CCR2/5 on macrophages and HSC (figure 3) and is currently developed as anti-inflammatory/anti-fibrotic treatment in NASH and other indications.218 Despite encouraging interim data after 1 year,219 final analysis after 2 years revealed that a no treatment arm was no more effective than a placebo.220 In a phase 3 study (URORA, NCT03028740) was terminated early due to lack of efficacy, but CVC is still investigated in combination strategies (eg, FXR agonist tropifexor/TANDEM trial see above). Pharmacological or genetic inhibition of peribiliary macrophage recruitment attenuated liver injury and fibrosis in mouse models of PSC.221 Interestingly, microbe-stimulated monocytes drive Th17 differentiation in vitro and induce cholangiocytes to produce chemokines mediating recruitment of Th17 cells and more monocytes into portal tracts.222 Interestingly, Th17 cells may also be involved in NASH progression223 and, securinumab, a monoclonal antibody against IL17A, is currently investigated in patients with psoriasis and coexisting NAFLD (NCT04237116). In a rodent model combination of all-trans retinoic acid and CVC synergistically reduced liver fibrosis and bile duct injury, although a reduction in neutrophils and T cells but not macrophages was observed.224 Recently, an open label,
Recent advances in clinical practice

proof of concept phase 2 study with CVC in patients with PSC (PERSEUS trial, NCT02653625) has been completed with negative results (table 1).

**SIMTUZUMAB AS ANTIFIBROTIC STRATEGY**

Simtuzumab is a humanised monoclonal antibody against lysyl oxidase-like 2 (LOXL2), which has raised much hope for treatment of fibrosis in both NASH and PSC, since LOXL2 contributes to fibrogenesis by cross-linkage of collagen and regulates bile duct permeability.225 226 In patients with PSC and NASH increased serum levels of LOXL2 correlate with more advanced fibrosis and severity of portal hypertension.226 227 Despite these encouraging findings, simtuzumab failed to show antifibrotic effects in NASH patients with bridging fibrosis or compensated cirrhosis228 and in patients with PSC228 (table 1). However, despite being ‘negative’ the biomaterial and data obtained during these clinical trials have provided important pathogenetic and clinical insights into these diseases.24 25 Other antifibrotic strategies have recently been reviewed elsewhere in more detail.230 231

**CONCLUSIONS**

A better understanding of the pathogenesis of cholestatic and metabolic liver diseases has crossfertilised drug development for both disease areas. Several novel therapeutic approaches for cholestatic and fatty liver diseases currently investigated in phase 2 and 3 clinical trials are based on shared pathogenetic and therapeutic principles (table 1). Due to the central role of NRs and BAAs as integrators of metabolism and inflammation, targeting these pathways has great potential. Some of these approaches have already resulted in first encouraging results (table 1) and even conditional approval of novel therapies, but their long-term efficacy, tolerability and safety still needs to be evaluated. Apart from therapeutic efficacy a positive impact on pruritus in cholestatic disorders (seen with fibrates) and beneficial cardiometabolic profile in NASH (seen with PPAR and THR-B1 ligands) is an important aspect for considering long-term treatment with these drugs. Based on the complex pathophysiology of cholestatic and fatty liver diseases and the multiple pathways involved in their progression, multitargeted treatments or combination therapies that engage different targets are urgently required. Several of the currently explored drugs (eg, NR ligands) simultaneously target multiple key pathogenetic processes and may show even synergistic effects when combined in the management of these disorders, for example, combining FXR and PPAR ligands in PBC232 233 and NASH.234 235 Interestingly, in extension of dual PPARα/γ and α/δ agonists, dual FXR/PPARδ agonists are currently developed for treatment of NASH.235 As broadly acting drugs NR (eg, FXR) ligands are also explored in combination with anti-diabetic (eg, GLP-1 RA; SGLT2 inhibitors) or anti-inflammatory drugs (eg, CVC) to achieve a higher therapeutic efficacy in NASH which is still in an unsatisfactory range for single agents.236 Apart from combining existing drugs, the development of dual GLP-1/glucagon receptor or GLP-1/GIP agonists or even triagonists237 with first promising results in NASH237–239 may show up another promising approach in drug development. Notably, these peptide hormones can be combined with NR ligands thus increasing the efficacy in target organs while at the same time restricting side effects.237 A major challenge will be to test the plethora of therapeutic options which requires innovative designs such as basket trials.240

**Correction notice** This article has been corrected since it published Online First. The corresponding address has been amended and the heading ‘notUDCA as paradigm cholehepatic drug’ added.

**Contributors** Concept and supervision: MT; drafting of the manuscript; MT; critical revision of the manuscript for important intellectual content: MT and CDF; obtained funding: MT; material support: CDF and MT. The authors thank Alexandra Weisgram for editorial assistance.

**Funding** This work was supported by the grants F7310-821 and I7255-B30 from the Austrian Science Foundation (to MT).


**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Michael Trauner http://orcid.org/0000-0002-1275-6425

**REFERENCES**


Recent advances in clinical practice


175 FDA lifts all clinical holds on Seladelpar. Available: https://www.fda.gov/newsroom/pressannouncements/fda-lifts-all-clinical-holds-on-seladelpar.html


